Quality and Innovation
The RFC stands as a beacon for researchers seeking to push the boundaries of RNA research. By providing a comprehensive suite of IVT RNA modalities, compatible with nearly any gene imaginable, we empower scientific advancements in translational drug research.
Design, develop, and deliver
Our comprehensive suite of professional services covers all your RNA needs. From state-of-the-art template design, advanced RNA quality control and LNP formulations, we are your all-inclusive everything IVT expert.
Reporter RNA
Source your bioluminescent, fluorescent, or antigen marker RNAs for UBC, from UBC.
Template Design
Have your ideas converted into DNA templates straight from screen to doorstep.
RNA modalities
Work with our team to choose the right IVT RNA modality for your project – mRNA, saRNA, or circRNA.
Quality Control
Ease your worries with our standard and deluxe RNA QC packages.
Advanced RNA QC Services
Access our RNA QC services to expand your quality control capabilities.
LNP Formulation
Ready to deliver your RNA in-vivo? We work with the Cullis NanoMedicines Research Group to have your RNA encapsulated and ready for testing.
Hear from our clients
Tried and trusted by researchers worldwide
“We chose UBC for our RNA manufacturing and LNP formulation for three reasons: their researchers are luminaries in RNA therapeutics and LNP delivery systems, they offered competitive pricing, and they provided white-glove service with rapid response times from expert scientists. UBC’s RNA and LNP products jumpstarted our R&D roadmap, shaving months off the time needed to develop our lead candidate. The quality of their manufactured products was top-notch, and their team’s communication was always clear, professional, and always helpful.”
Matt Zehnder
CEO, Pasture Biosciences
Cedric Brimacombe“We chose to use the UBC RNA core for our in vivo grade mRNA needs as they are a local Vancouver-based source that services industry needs. The RNA core provided excellent service – they assisted with design and optimization of RNA constructs from our supplied amino acid sequence and produced high quality material that had excellent expression in vivo and fully met our needs. The timeline for turnover was faster than larger commercial suppliers, and responses and flexibility with timing and the occasional need for more material on short notice has been nothing short of excellent. Communication, accuracy and clarity have all been great. The RNA core has been an excellent source of pre-clinical mRNA and we would highly recommend them to others looking for these services.”
Director of Business Development, Polymorphic Bio
“The RFC led by Dr. Andrew Varley provides a reliable source for RNA for my projects to develop LNP formulation at the Cullis lab. RFC ensures timely delivery of high-quality RNA with comprehensive QC reports. The ongoing support from and proactive communication with Dr. Varley and team has been accelerating my research!”
Suiyang Liao
Postdoctoral Fellow, Pieter Cullis Lab Group
“The UBC RNA and Formulation Core has consistently exceeded our expectations through their outstanding service and expertise. Their high-quality mRNA and exceptional turnaround times have allowed us to complete our projects quickly and efficiently. What sets the RFC apart is how invested they are in their clients’ success – from finding innovative solutions to project-specific challenges to developing more efficient production processes that lower the costs for researchers. Their combination of scientific expertise, communication and reliable service makes them an invaluable research partner.”
Daniel Andrews
Postdoctoral Fellow, Cerecura Nanotherapeutics
“UBC has been more than a vendor – they pretty much functioned like an extension of our lab. As a small biotech startup, we rely on partners who can move quickly and adapt to our needs. The UBC mRNA and LNP teams have been exceptional – delivering mRNA constructs and formulations on short timelines, often responding within minutes, and working with custom requests. They worked with us in the design phase, helped us refine our formulation strategy, and we plan to continue working with them as we scale to large animal studies.”
Lada Nuzhna
CEO, Epi Labs